The P-I/II (MATINS) study evaluates bexmarilimab as monothx. in 90 patients with 10 solid tumor cohorts who received 3 courses of treatment & had scheduled tumor imaging at cycle 4 & completed 12mos. survival follow-up
The results showed that 65% of patients were alive who benefited from treatment with bexmarilimab @12mos. over 11% who did not benefit, the strongest survival benefit was observed, 12mos. survival (100% in benefited patients vs 0% who did not benefit), was well tolerated with no new safety signals & no TRAEs that resulted in a decrease or modification of dosing
Bexmarilimab is wholly-owned precision immunotherapy that provides long-term immune stimulation for cancers by targeting myeloid cell function
Ref: Cision | Image: Faron
